MonTa Biosciences was awarded with positive feedback from the regulatory agency in Denmark to initiate phase I study on our lead candidate MBS8. The study will start later in Q1 with dosing of solid tumor patients in a dose-escalation study. The primary endpoint is to establish the recommended phase 2 dose level, for which the second part of the study, the expansion stage, will include a larger group of different solid tumor patients.
